The Food & Drug Administration has cleared drug therapy called Carvykti, the first treatment for blood cancer in the U.S. It works on patients with multiple melanoma whose disease has worsened despite prior treatment with other drugs. On one of J&J’s U.S. studies, 98% of the 97 multiple-myeloma patients treated with Carvykti had a significand reduction in the proteins that signal the presence of myeloma. And 83% had a complete remission, with no detectable cancer cells at a median time point of 22 months after treatment.